Kaplan Meier Estimates | |||||
---|---|---|---|---|---|
5-Year Absence of Hepatic Decompensation (%) | After Propensity Score Matching | ||||
Metformin | Metformin + SGLT2-I | P | HR (95%CI) | ||
All | 87.62 | 92.22 | 0.017 | 0.63 (0.43–0.93) | |
Subgroup a | |||||
Men | 87.42 | 87.78 | 0.477 | 0.83 (0.51–1.37) | |
Women | 88.72 | 96.02 | 0.086 | 0.57 (0.29–1.09) | |
White | 87.43 | 92.51 | < 0.01 | 0.49 (0.31–0.76) | |
Non-White | 93.05 | 94.31 | 0.105 | 0.43 (0.15–1.23) | |
Hispanic | 91.82 | 98.4 | 0.230 | 0.39 (0.08–1.92) | |
Non-Hispanic | 87.84 | 91.53 | 0.185 | 0.73 (0.46–1.16) | |
Age 39–59 | 94.86 | 95.08 | 0.708 | 1.18 (0.51–2.7) | |
Age 60–80 | 85.84 | 90.98 | < 0.01 | 0.53 (0.33–0.85) | |
MASH b | 95.39 | 97.43 | 0.124 | 0.52 (0.22–1.22) |